Details
Stereochemistry | RACEMIC |
Molecular Formula | C8H18NO2.Cl |
Molecular Weight | 195.687 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].CC(C[N+](C)(C)C)OC(C)=O
InChI
InChIKey=JHPHVAVFUYTVCL-UHFFFAOYSA-M
InChI=1S/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C8H18NO2 |
Molecular Weight | 160.234 |
Charge | 1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17565027Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17565027
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546
Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546 |
59.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | PROVOCHOLINE Approved UseProvocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma. Launch Date1986 |
Doses
Dose | Population | Adverse events |
---|---|---|
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
Disc. AE: Bronchoconstriction... AEs leading to discontinuation/dose reduction: Bronchoconstriction (severe) Sources: Page: p.1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bronchoconstriction | severe Disc. AE |
16 mg/mL 5 times / day multiple, respiratory (max) Recommended Dose: 16 mg/mL, 5 times / day Route: respiratory Route: multiple Dose: 16 mg/mL, 5 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Bronchial airway hyperreactivity Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Noninvasive method to measure airway obstruction in nonanesthetized allergen-sensitized and challenged mice. | 2001 |
|
The effect of acute alteration in oxygen tension on the bronchodilator response to salbutamol in vitro and in vivo in man. | 2001 |
|
Airway foreign body with clinical features mimicking bronchial asthma. | 2001 |
|
Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. | 2001 Apr |
|
Changes in indices of airway hyperresponsiveness during one year of treatment with inhaled corticosteroids in patients with asthma. | 2001 Apr |
|
Increased frequency of Chlamydia pneumoniae antibodies in patients with asthma. | 2001 Apr |
|
Glucocorticoid treatment increases inhibitory m(2) muscarinic receptor expression and function in the airways. | 2001 Apr |
|
Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families. | 2001 Apr |
|
Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. | 2001 Apr |
|
Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma. | 2001 Apr |
|
Effects of smooth muscle activation on axial mechanical properties of excised canine bronchi. | 2001 Apr |
|
Hexachlorobenzene-induced eosinophilic and granulomatous lung inflammation is associated with in vivo airways hyperresponsiveness in the Brown Norway rat. | 2001 Apr 1 |
|
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). | 2001 Apr 15 |
|
Respiratory effects of a single dive to 50 meters in sport divers with asymptomatic respiratory atopy. | 2001 Feb |
|
G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. | 2001 Feb |
|
The lack of the bronchoprotective and not the bronchodilatory ability of deep inspiration is associated with airway hyperresponsiveness. | 2001 Feb |
|
Protective effects of volatile agents against methacholine-induced bronchoconstriction in rats. | 2001 Feb |
|
Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition. | 2001 Feb |
|
Endotoxin responsiveness and subchronic grain dust-induced airway disease. | 2001 Feb |
|
Impaired endothelium-dependent vasodilatation in renal failure in humans. | 2001 Feb |
|
Bronchoconstriction induced by inhaled adenosine 5'-monophosphate in subjects with allergic rhinitis. | 2001 Jan |
|
Methacholine inhalation challenge: a shorter, cheaper and safe approach. | 2001 Jan |
|
ATS guidelines for methacholine and exercise challenge testing. | 2001 Jan |
|
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. | 2001 Jan |
|
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. | 2001 Jan |
|
Linkage between bronchial responsiveness to methacholine and gene markers of IL-4 cytokine gene cluster and T-cell receptor alpha/delta gene complex in Korean nuclear families. | 2001 Jan |
|
[Asthma related to inhalation of Plantago ovata]. | 2001 Jan 13 |
|
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung. | 2001 Jun |
|
SCF-induced airway hyperreactivity is dependent on leukotriene production. | 2001 Jun |
|
Possible involvement of Rho kinase in Ca2+ sensitization and mobilization by MCh in tracheal smooth muscle. | 2001 Jun |
|
Regulation of secretion from mucous and serous cells in the excised ferret trachea. | 2001 Jun |
|
Effects of BCG on ovalbumin-induced bronchial hyperreactivity in a guinea pig asthma model. | 2001 Mar |
|
Correlation between airway hyperresponsiveness and airway inflammation in a young adult population: eosinophil, ECP, and cytokine levels in induced sputum. | 2001 Mar |
|
High-resolution computed tomographic evaluation of airway distensibility and the effects of lung inflation on airway caliber in healthy subjects and individuals with asthma. | 2001 Mar |
|
Incidence and host determinants of probable occupational asthma in apprentices exposed to laboratory animals. | 2001 Mar |
|
Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge. | 2001 Mar |
|
Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). | 2001 Mar |
|
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice. | 2001 Mar |
|
Drug treatment of airway inflammation in asthma. | 2001 Mar |
|
Polycystic ovary syndrome is associated with endothelial dysfunction. | 2001 Mar 13 |
|
Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. | 2001 Mar 27 |
|
Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. | 2001 Mar 9 |
|
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus. | 2001 May |
|
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. | 2001 May |
|
Occupational asthma caused by exposure to cyanoacrylate. | 2001 May |
|
Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults. | 2001 May |
|
Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. | 2001 May |
|
Incidence of sensitization, symptoms, and probable occupational rhinoconjunctivitis and asthma in apprentices starting exposure to latex. | 2001 May |
|
Inhibition of m3 muscarinic acetylcholine receptors by local anaesthetics. | 2001 May |
|
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. | 2001 May |
Patents
Sample Use Guides
Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9622546
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:35:48 GMT 2023
by
admin
on
Fri Dec 15 16:35:48 GMT 2023
|
Record UNII |
0W5ETF9M2K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1937
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
40165
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB08832MIG
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
0W5ETF9M2K
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
C47607
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
1396364
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
DTXSID7023271
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
3161
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
200-537-2
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL978
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
D016210
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
62-51-1
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
6114
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
m7282
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
DBSALT001175
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
0W5ETF9M2K
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
757090
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
100000081225
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY | |||
|
50142
Created by
admin on Fri Dec 15 16:35:48 GMT 2023 , Edited by admin on Fri Dec 15 16:35:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
USP
|
||
|
IMPURITY -> PARENT |
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |